易瑞沙（吉非替尼片、IRESSA）

Iressa (gefitinib tablets, IRESSA) is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has previously received chemotherapy. Previous chemotherapy mainly refers to platinum and docetaxel treatment.

[Model and Specification]
250mg/tablet, 30 tablets/box.

[Usage and Dosage]
The recommended dose of Iressa IRESSA is 250mg (1 tablet), once a day

[Adverse Reactions and Contraindications]
The most common (incidence rate of more than 20%) adverse drug reactions (ADRs) are diarrhea and skin reactions (including rash, acne, dry skin and itching), which are generally seen within the first month after taking the drug and are usually reversible. About 8% of patients experience severe adverse drug reactions (CTC standard 3 or 4). About 3% of patients stop treatment due to ADR.

[Contraindications]
Those who are known to have severe allergic reactions to the active substance or any excipient of the product.

[Storage]
Store at room temperature.

【Manufacturer】
Developed and produced by AstraZeneca Pharmaceuticals.